Clinical utilization of cinacalcet in hypercalcemic conditions

Bibliography

• Chang W, Shoback D. Extracellular Ca2+ sensing receptors – an overview. Cell Calcium 2004;35:183-96
   PubMed Web of Science ®Google Scholar
• Goodman WG, Frazao JM, Goodkin DA, A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000;58:436-45
   PubMed Web of Science ®Google Scholar
• Charytan C, Coburn JW, Chonchol M, Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 2005;46:58-67
   PubMed Web of Science ®Google Scholar
• Bushinsky DA, Monk RD. Electrolyte quintet: calcium. Lancet 1998;352:306-11
   PubMed Web of Science ®Google Scholar
• Messa P, Alfieri C, Brezzi B. Cinacalcet: pharmacological and clinical aspects. Expert Opin Drug Metab Toxicol 2008;4(12):1551-60
   PubMed Web of Science ®Google Scholar
• House MG, Kohlmeier L, Chattopadhyay N, Expression of an extracellular calcium-sensing receptor in human and mouse bone marrow cells. J Bone Miner Res 1997;12:1959-70
   PubMed Web of Science ®Google Scholar
• Ye CP, Yamaguchi T, Chattopadhyay N, Extracellular calcium-sensing-receptor (CaR)-mediated opening of an outward K (+) channel in murine MC3T3-E1 osteoblastic cells: evidence for expression of a functional CaR. Bone 2000;27(1):21-7
   PubMed Web of Science ®Google Scholar
• Dvorak MM, Riccardi D. Ca2+ as an extracellular signal in bone. Cell Calcium 2004;35(3):249-55
   PubMed Web of Science ®Google Scholar
• Tu Q, Pi M, Karsenty G, Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto Gcm2 null background. J Clin Invest 2003;111:1029-37
   PubMed Web of Science ®Google Scholar
• Kos CH, Karaplis AC, Peng JB, The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest 2003;111:1021-8
   PubMed Web of Science ®Google Scholar
• Rodriguez L, Tu C, Cheng Z, Expression and functional assessment of an alternatively spliced extracellular Ca2+-sensing receptor in growth plate condrocytes. Endocrinology 2005;146:5294-303
   PubMed Web of Science ®Google Scholar
• Chang W, Tu C, Chen TH, The extracellular Calcium-sensing receptor (CaSR) is a critical modulator of skeletal development. Science Signal 2008;1:1-12
   PubMedGoogle Scholar
• Kantham L, Quinn SJ, Egbuna OI, The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion. Am J Physiol Renal Physiol 2009;297:E915-23
   Web of Science ®Google Scholar
• Egbuna OI, Quinn SJ, Kantham L, The full-length calcium-sensing receptor dampens the calcemic response to 1alpha,25(OH)2 vitamin D3 in vivo independently of parathyroid hormone. Am J Physiol Renal Physiol 2009;297:F720-8
   PubMed Web of Science ®Google Scholar
• Marie PJ The calcium-sensing receptor in bone cells. a potential therapeutic target in osteoporosis. Bone 2010;46:571-6
   PubMed Web of Science ®Google Scholar
• Padhi D, Salfi M, Harris RZ. The Pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals. Am J Ther 2007;14:235-40
   PubMedGoogle Scholar
• Kumar GN, Sproul C, Poppe L, Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models. Drug Metab Dispos 2004;32:1491-500
   PubMed Web of Science ®Google Scholar
• Padhi D, Harris RZ, Salfi M, Pharmacokinetics and pharmacodynamic of cinacalcet in hepatic impairment: phase I, open-label, parallel group, single-dose, single-centre study. Clin Drug Invest 2008;28(10):635-43
   PubMed Web of Science ®Google Scholar
• Harris RZ, Salfi M, Sullivan JT, Padhi D. Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. Clin Pharmacokinet 2007;46:495-501
   PubMed Web of Science ®Google Scholar
• Nakashima D, Takama H, Ogasawara Y, Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of destromethorphan: in vitro and clinical studies. J Clin Pharmacol 2007;47:1311-19
   PubMed Web of Science ®Google Scholar
• Harris RZ, Padhi D, Marbury TC, Pharmacokinetics, pharmacodynamic, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 2004;44:1070-6
   PubMed Web of Science ®Google Scholar
• Padhi D, Harris R. Clinical Pharmacokinetic and Pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet 2009;48:303-11
   PubMed Web of Science ®Google Scholar
• Serra AL, Braun SC, Starke A, Pharmacokinetics and Pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant 2008;8:803-10
   PubMed Web of Science ®Google Scholar
• Kamar N, Gennero I, Spataru L, Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose. Nephrol Dial Transplant 2008;23:3720-6
   PubMed Web of Science ®Google Scholar
• Sattler M, Guengerich FP, Yun CH, Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-61
   PubMed Web of Science ®Google Scholar
• Kruse AE, Eisenberger U, Frey FJ, The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005;20:1311-14
   PubMed Web of Science ®Google Scholar
• Serra AL, Schwarz AA,Wick FH, Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005;20:1315-19
   PubMed Web of Science ®Google Scholar
• Falck P, Vethe NT, Asberg A, Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant 2008;23:1048-53
   PubMed Web of Science ®Google Scholar
• Maass E, Mueller GA, Heller T, Koziolek MJ. Decrease in serum tacrolimus level and rise in serum creatinine under late addition of cinacalcet in a renal transplant recipient with hyperparathyroidism: a case report. Transplant Proc 2007;39:3468-70
   PubMed Web of Science ®Google Scholar
• Christians U, Kohlhaw K, Budniak J, Ciclosporin metabolite pattern in blood and urine of liver graft recipients. I. Association of ciclosporin metabolites with nephrotoxicity. Eur J Clin Pharmacol 1991;41:285-90
   PubMed Web of Science ®Google Scholar
• Messa P, Sindici C, Cannella G, Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998;54:1704-13
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Bammens B, Claes K, Measuring total blood calcium displays a low sensitivity for the diagnosis of hypercalcemia in incident renal transplant recipients. Clin J Am Soc Nephrol 2010;11:2085-92
   Google Scholar
• Gwinner W, Suppa S, Mengel M, Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005;5(8):1934-41
   PubMed Web of Science ®Google Scholar
• Pinheiro HS, Camara NO, Osaki KS, Early presence of calcium oxalate deposition in kidney graft biopsies is associated with poor long-term graft survival. Am J Transplant 2005;5(2):323-9
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Claes K, Kuypers DR, Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrol Dial Transplant 2007;22(6):1730-7
   PubMed Web of Science ®Google Scholar
• Kandil E, Florman S, Alabbas H, Exploring the effect of parathyroidectomy for tertiary hyperparathyroidism after kidney transplantation. Am J Med Sci 2010;339:420-4
   PubMed Web of Science ®Google Scholar
• Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 2009;24(3):982-9
   PubMed Web of Science ®Google Scholar
• Komaba H, Nakanishi S, Fujimori A, Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010. [Epub ahead of print]
   Google Scholar
• Gomez Marques G, Obrador Mulet A, Vilar Gimeno A, Treatment with cinacalcet of secondary hyperparathyroidism after renal transplantation. Transplant Proc 2009;41(6):2139-43
   PubMed Web of Science ®Google Scholar
• Copley JB, Germain M, Stern L, Evaluation of cinacalcet HCl treatment after kidney transplantation. Transplant Proc 2010;42:2503-8
   PubMed Web of Science ®Google Scholar
• Borchhardt KA, Heinzl H, Mayerwoger E, Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation 2008;86:919-24
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Naesens M, Claes K, Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007;7:1193-200
   PubMed Web of Science ®Google Scholar
• Rojas E, Carlini RG, Clesca P, The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int 2003;63:1915-23
   PubMed Web of Science ®Google Scholar
• Bergua C, Torregrosa JV, Fuster D, Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 2008;86(3):413-17
   PubMed Web of Science ®Google Scholar
• Borchhardt KA, Diarra D, Sulzbacher I, Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Nephrol 2010;31:482-9
   PubMed Web of Science ®Google Scholar
• Bilezikian JP, Khan AA, Potts JT Jr. Third international workshop on the management of asymptomatic primary hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009;94:335-9
   PubMed Web of Science ®Google Scholar
• Shoback DM, Bilezikian JP, Turner SA, The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:5644-9
   PubMed Web of Science ®Google Scholar
• Peacock M, Bilezikian JP, Klassen PS, Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:135-41
   PubMed Web of Science ®Google Scholar
• Peacock M, Bolognese MA, Borofsky M, Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009;94:4860-7
   PubMed Web of Science ®Google Scholar
• Sajid-Crockett S, Singer FR, Hershman JM. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism 2008;57(4):517-21
   PubMed Web of Science ®Google Scholar
• Iglesias P, Ais G, Gonzalez A, Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy. Am J Med Sci 2008;335:111-14
   PubMed Web of Science ®Google Scholar
• Marcocci C, Chanson P, Shoback D, Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 2009;94:2766-72
   PubMed Web of Science ®Google Scholar
• Falchetti A, Cilotti A, Vaggelli L, A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nat Clin Pract Endocrinol Metab 2008;4:351-7
   PubMedGoogle Scholar
• Moyes VJ, Monson JP, Chew SL, Akker SA. Clinical use of cinacalcet in MEN1 Hyperparathyroidism. Int J Endocrinol 2010. [Epub ahead of print]
   Google Scholar
• Shangold MM, Dor N, Welt SI, Hyperparathyroidism and pregnancy: a review. Obstet Gynecol Surv 1982;37:217-28
   PubMedGoogle Scholar
• Schnatz PF, Curry SL. Primary hyperparathyroidism in pregnancy: evidence-based management. Obstet Gynecol Surv 2002;57:365-76
   PubMed Web of Science ®Google Scholar
• Horjus C, Groot I, Telting D, Cinacalcet for hyperparathyroidism in pregnancy and puerperium. J Pediatr Endocrinol Metab 2009;22:741-9
   PubMed Web of Science ®Google Scholar
• Fanari Z, Kadikoy H, Haque W, Medical management of primary hyperparathyroidism with concomitant multiple myeloma. Intern Med 2010;49:581-4
   PubMed Web of Science ®Google Scholar
• Lietman SA, Tenenbaum-Rakover Y, Jap TS, A novel loss-of-function mutation, Gln459Arg, of the calcium-sensing receptor gene associated with apparent autosomal recessive inheritance of familial hypocalciuric hypercalcemia. J Clin Endocrinol Metab 2009;94:4372-9
   PubMed Web of Science ®Google Scholar
• Nanjo K, Nagai S, Shimizu C, Identification and functional analysis of novel calcium-sensing receptor gene mutation in familial hypocalciuric hypercalcemia. Endocr J 2010;57:787-92
   PubMed Web of Science ®Google Scholar
• Timmers HJ, Karperien M, Hamdy NA, Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. J Intern Med 2006;260:177-82
   PubMed Web of Science ®Google Scholar
• Lu JY, Yang Y, Gnacadja G, Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor. J Pharmacol Exp Ther 2009;331:775-86
   PubMed Web of Science ®Google Scholar